DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients

Information source: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Thyroid Cancer

Intervention: Thyrogen, thyroid hormone withdrawal, iode 131 (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Gustave Roussy, Cancer Campus, Grand Paris

Official(s) and/or principal investigator(s):
Martin SCHLUMBERGER, PhD, Principal Investigator, Affiliation: Gustave Roussy, Cancer Campus, Grand Paris

Overall contact:
Martin SHCLUMBERGER, PhD, Phone: 00 33 014-211-6095, Email: schlumbg@igr.fr

Summary

In France, 3,700 new cases of thyroid cancer are diagnosed each year. Differentiated thyroid carcinoma represents more than 90% of all thyroid cancers; and has a 10-year survival of 90-95% of patients. This favorable prognosis is the result of an effective primary therapy, which consists of a total thyroidectomy that is followed by radio-iodine ablation with 3,7GBq (100mCi) in case of significant risk of persistent disease. Few centers investigated the possibility to administer lower doses of 131I (1GBq, 30 mCi), in order to limit the potential long-term adverse complications for patients and to respond to radioprotection rules for family members and medical staff. Radio-iodine ablation requires TSH stimulation, which was historically achieved by thyroid hormone withdrawal for 3 to 5 weeks. During this period, patients suffered from symptoms of hypothyroidism. The recombinant human TSH (rhTSH, Thyrogen®, Genzyme Therapeutics, Cambridge, USA) was approved in Europe in 2005 as an alternative stimulation procedure to withdrawal during ablation. It allows patients to remain euthyroid on thyroid hormone therapy (that needs not to be withdrawn). However, this a costly drug (800 € per patient), whose economic efficiency needs to be checked.

Clinical Details

Official title: Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: the rate of successful postoperative thyroid ablation

Secondary outcome:

the rate of long-term complications

specific toxicities

management costs (hospitalization, diagnosis tests and sick leave)

quality of life and utility

Detailed description: This is a multicentric, randomized, controlled, open-label phase III clinical trial involving 26 French centers. It aims at comparing four strategies of management of postoperative radioiodine ablation, each strategy combining a method of TSH stimulation (thyroid hormone withdrawal or rhTSH (Thyrogen®, Genzyme)) and an activity of 131I (low-dose (1GBq, 30 mCi) or high-dose (3,7GBq, 100 mCi)).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18 year or older

- Newly diagnosed differentiated papillary or follicular thyroid carcinoma who

underwent total thyroidectomy between 30 and 60 days before randomization and treated by LT4 for at least one month.

- Patients are all staged pT1<1cm N1 or pT1>1cm N0 N1 Nx or pT2 N0

- The performance status is 0 or 1.

- All patients will provide written consent to participate.

Exclusion Criteria :

- partial thyroidectomy

- patients treated by LT4 less than one month

- time from thyroidectomy superior to 60 days at randomization

- patients with Hurtle cancer or aggressive histology

- Patients staged pT1<1cm N0 or T2 N1 or T3 or T4 or M1

- patients for which the use of rhTSH is required for medical reasons

- patients with major concurrent medical disorder (cardiac, renal, liver, respiratory)

- patients with other malignancies (exception for in situ cervix uterine cancer, baso

cellular skin cancer or breast cancer in remission for at least 2 years)

- patients with recent history of drugs affecting thyroid function, including iodine

containing medications or radiocontrast agents

- patients with recent history of 131I whole body scan

- pregant women or breast-feeding

Locations and Contacts

Martin SHCLUMBERGER, PhD, Phone: 00 33 014-211-6095, Email: schlumbg@igr.fr

Institut Gustave Roussy, Villejuif 94800, France; Not yet recruiting
Martin SCHLUMBERGER, PhD, Phone: 00 33 014-211-6095, Email: schlumbg@igr.fr
Additional Information

Starting date: February 2007
Last updated: February 16, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017